Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05866302 · ClinicalTrials.gov registry record
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
A clinical trial of Graft-Versus-Host Disease and Chronic Lung Disease, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- 375
- Enrollment target
- 6
- Study locations
NCT05866302: Recruiting study of Graft-Versus-Host Disease and Chronic Lung Disease, sponsored by University of Michigan Rogel Cancer Center.
NCT05866302 is a study of Graft-Versus-Host Disease and Chronic Lung Disease that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 375 participants, above the 73-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (414% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05866302, a study of Graft-Versus-Host Disease and Chronic Lung Disease, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- 375 participants
- Enrollment target
- 6
- Study locations
Study Summary
The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metrics at the onset of chronic GVHD and determine if a PRM signature is present that will predict 1-year CLD free survival. For cohort 2, the primary objective will focus on characterizing PRM at the onset of CLD and determine if PRM can predict the trajectory in lung function decline in affected patients.
Primary Outcome
The time to develop CLD or death over 12 months of follow-up in both pediatric and adult subjects will be determined. we will classify subjects into comparison groups of (1) high PRMfSAD (\>30%), (2) high PRMPD (\>40%) or (3) neither high PRMfSAD nor high PRMPD (PRMNorm group). The two primary analyses are to compare 1-year CLD-free survival between the high PRMfSAD and PRMNorm groups and separately between the high PRMPD and PRMNorm groups, using two-sided, two-sample logrank tests with an over
Conditions Studied
Study Locations (6)
California
- Stanford Hospital - Stanford
Georgia
- Emory University - Atlanta
Massachusetts
- Dana Farber - Boston
Michigan
- The University of Michigan Cancer Center - Ann Arbor
Texas
- MD Anderson - Houston
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2028-05 |
What NCT05866302 shows while recruiting
NCT05866302 is an observational study that tracks outcomes without assigning an intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, above the 73-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (414% higher).
The record links to 3 conditions, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 0 interventions.
NCT05866302 lists 6 locations in 6 states (California, Georgia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05866302 about?
NCT05866302 is a clinical study titled "Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients". The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metr...
What is the current status of trial NCT05866302?
This trial is currently recruiting. The enrollment target is 375 participants. The study started on 2023-05-30. Estimated completion is 2028-05.
What conditions does trial NCT05866302 study?
This clinical trial studies the following conditions: Graft-Versus-Host Disease, Chronic Lung Disease, Hematopoietic Cell Transplantation.
Who is sponsoring clinical trial NCT05866302?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05866302 being conducted?
This trial has 6 study locations across California, Georgia, Massachusetts, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft-Versus-Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05866302's enrollment target sits among peer trials
375 3rd of 38 higher than 36 of 38 other Graft-Versus-Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft-Versus-Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
RECRUITING
-
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
RECRUITING · Phase 2
-
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 1
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls
RECRUITING
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI